Pancreatic Cancer Therapeutics Markets To Rise At A Moderate CAGR Of 7.6% From $1.746bn In 2014 To $2.92bn In 2021
Pancreatic Cancer (PC) is a disease predominately of the elderly with ~75% of PC cases being diagnosed in patient’s over 75 years old. PC proliferates rapidly, is asymptomatic at its earliest stages and when symptoms do present themselves they are non-specific. There are currently no early detection methods in use for PC. Currently the best option for patient survival is resection which can triple five year survival rate to 15% compared to the unresectable stages of PC.
Regrettably ~83% of patients present with advanced unresectable disease and patient prognosis is extremely poor. The majority of patients ultimately develop resistant disease, for whom treatment options have historically been limited, with treatment involving fluorouracil as a monotherapy or used in a combination therapy being standard. The recent approval of Onivyde for gemcitabine refractory disease in 2015 has improved survival of resistant patients, but there is a clear clinical need to diversify the treatment options for this patient cohort.
The current late-stage drugs in development for PC address this clinical need; however, results so far have been limited in their efficacy, with none demonstrating clinically transformative efficacy or safety. As a result, the growth in PC prevalence as a result of a global aging population, increasing diabetes and obesity prevalence is expected to be the key driver of this market throughout the forecast period.
Global revenues for the PC market are forecast to rise at a moderate CAGR of 7.6% from $1.746bn in 2014 to $2.92bn in 2021.
What factors are driving the market growth?
How can the factors limiting growth be overcome in the future?
The variation in mechanism of action has shifted away from the traditional chemotherapies, which dominate the marketed products, but account for only 7% of the pipeline. 44% of the pipeline are drugs inhibiting signal transduction.
What are the dynamics of the remaining 49% of the pipeline?
How does this reflect the need for novel targeted therapies?
To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=499497
Key mechanisms of action across the pipeline include cancer immunotherapies against IAP repeat containing proteins, whole cell vaccines and targeted therapies against the PI3K/Akt/mTOR pathway.
What is the scientific rationale behind these targets?
Several drugs are expected to be approved during the forecast period: TH-302, ruxolitinib phosphate, HyperAcute Pancreas, G17DT and clivatuzumab tetraxetan. However, their sales will be limited by their expected high costs.
Where will these novel therapies fit into the current treatment algorithm for PC?
The pipeline therapies, G17DT is expected to have the strongest performance, with revenues of $141m by 2021.
How will the other late stage pipeline drugs perform commercially?
Reasons to buy
This report will allow you to
Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis.
Visualize the composition of the pancreatic cancer market in terms of dominant molecule types and targets, highlighting the current unmet needs and how they can be addressed to allow a competitive understanding of gaps in the current market.
Analyze the pancreatic cancer pipeline and stratify by stage of development, molecule type, and molecular target.
Visualize the clinical safety and efficacy of late-stage pipeline drugs via a detailed heat map, outlining the results across major clinical trial endpoints.
Understand the growth in patient epidemiology, annual therapy costs, and market revenues for the pancreatic cancer market globally and across the US, UK, France, Germany, Italy, Spain, Japan, and Canada.
Identify commercial opportunities in the pancreatic cancer deals landscape by analyzing trends in licensing and co-development deals.
Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=499497
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
90 State Street,
Albany NY - 12207
Website @ http://www.researchmoz.us/
Tel: 866-997-4948 (Us-Canada Toll Free)
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pancreatic Cancer Therapeutics Markets To Rise At A Moderate CAGR Of 7.6% From $1.746bn In 2014 To $2.92bn In 2021 here
News-ID: 527938 • Views: 183
More Releases from Pancreatic Cancer
Current Treatment Landscape, Unmet Needs, Pipeline And Commercial Opportunity In …
Researchmoz added Most up-to-date research on "Current Treatment Landscape, Unmet Needs, Pipeline And Commercial Opportunity In Pancreatic Cancer Market - Opportunity Analysis and Forecasts to 2017" to its huge collection of research reports. With five-year survival only approximately 5%, pancreatic cancer is characterized as a disease with some of the highest unmet need in oncology. This report focuses on the current treatment landscape, unmet needs, pipeline and commercial opportunity in the
Latest Research Report on Pancreatic Cancer - Identifying and Commercializing Fi …
Researchmoz added Most up-to-date research on "Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation" to its huge collection of research reports. Pancreatic cancer is the 12th most common cancer globally, and the fourth most fatal, with a mortality rate of 10.9 deaths per 100,000 people per year. The poor prognosis of pancreatic cancer patients has highlighted a significant need for new and improved approaches to treatment, which is not
Frontier Pharma: Pancreatic Cancer - Identifying And Commercializing First-In-Cl …
Pancreatic cancer is the 12th most common cancer globally, and the fourth most fatal, with a mortality rate of 10.9 deaths per 100,000 people per year. The poor prognosis of pancreatic cancer patients has highlighted a significant need for new and improved approaches to treatment, which is not being met by the current market. A highly active pancreatic cancer pipeline contains an array of products with varying molecule types and mechanisms
More Releases for CAGR
Cat Litter Box Market | CAGR of 9.1% | Revenue & CAGR of 9.1%
Cat Litter Box Market Report provides precise data about the market size, commercialization aspects and revenue forecast of the industry. The global Cat Litter Box market offers a historical factsheet relevant to the strategic mergers, acquirements, joint venture activities, and partnerships spread in the Cat Litter Box market. The most advanced data has been presented in the study on the revenue numbers, product details, and sales of the major firms.
Predictive Analytics Market Growing at Strong CAGR of CAGR of 25.31% 2019
Predictive analytics helps to extract information from the existing data. It helps in understanding the pattern and predict the trend or future for the organization. It uses what-if scenarios to predict possible risks involved in the future. Predictive analytics also helps in the optimization of the marketing campaigns and understanding of the customer behaviour for increasing the end-user response and to reduce the churn. Predictive analytics is segmented into: Risk management:
Global Absorption Chillers Market Reflecting a CAGR of 7.6% CAGR through 2025
The demand for thermally-driven chillers in multiple industrial verticals is poised to grow in the immediate future. Considering the rising demand for electrical chillers in commercial, residential as well as industrial settings, the adoption of absorption chillers will gain traction at considerable rate. By consuming lesser energy than conventional electrical chillers, absorption chillers will also garner surplus demand for not using ozone-depleting chlorofluorocarbons (CFC) for chilling purposes. Persistence Market Research’s
Aircraft Sensors Market Growing at a CAGR of 6.4% CAGR By 2022
The global aircraft sensors market is forecasted to receive a strong push in its growth momentum on the back of advancements in technologies, massive investments forwarded by private equity groups, and the elevation in the demand for aircraft. Adherence to the requirements and regulations of authorities such as local aircraft regulatory bodies and the Federal Aviation Administration (FAA) could pamper the growth of the market. Nonetheless, there could be more
China Baby Diapers Market Reflecting a CAGR of 19.1% CAGR 2012-2017
The increasing birth rate in China has proven to be a boon for the country’s baby diaper’s market. To provide a comprehensive analysis of the growth trajectory exhibited by the China baby diapers market and study the impact of the dynamic regulatory policies on the market, Transparency Market Research (TMR) has published a report, titled “Baby Diapers Market - China Industry Analysis, Market Size, Share, Growth, Trends And Forecast, 2012
Ecg Device Market Register a CAGR Growth of 4.1% CAGR by 2024
This region holds highest market share over the forecast period (2016-2024) and is expected to exhibit slow growth rate. The Asia Pacific is expected to be the fastest-growing region for ECG devices owing to its increasing incidence rate of cardiovascular diseases and high population. ECG devices are experiencing a paradigm technological shift from resting ECG systems to portable Holter monitoring systems, owing to their advantages of patient mobility, low prices and